OM Pharma SA – Trademark Portfolio

Entity Type: 99

OM Pharma SA holds 4 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 4 filings in this category. The portfolio also extends into Class 10 (Medical Apparatus) across 3 Nice Classification classes. Currently, 3 trademarks are registered. Notable registered marks include OMMUNITY and OM PHARMA.

Rue du Bois-du-Lan 22

CH-1217 Meyrin

4 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

OM Pharma SA's trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (4 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

10
Medical Apparatus (2 filings)

Surgical, medical, dental and veterinary apparatus and instruments

44
Medical Services (2 filings)

Medical services; veterinary services; hygienic and beauty care for human beings or animals

Frequently Asked Questions

How many trademarks does OM Pharma SA have?

OM Pharma SA has 4 U.S. trademarks filed with the USPTO. Of these, 3 registered.

What trademark classes does OM Pharma SA file in?

OM Pharma SA files trademarks across 3 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus), Class 44 (Medical Services). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are OM Pharma SA's most well-known trademarks?

OM Pharma SA's registered trademark portfolio includes well-known marks such as OMMUNITY and OM PHARMA. These are among 3 currently registered trademarks in the portfolio.

What is OM Pharma SA's trademark registration success rate?

OM Pharma SA has a 100% trademark registration rate, with 3 out of 3 resolved applications resulting in successful registration. Currently, 0 applications are pending review.